Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Why is Tagrisso not reimbursable as 1st-line treatment in Korea? < Hospital < Article - KBR
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | SpringerLink
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Osimertinib Continues to Impress With Response and Disease Control Rates in NSCLC
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
View of Osimertinib (Tagrisso) | Canadian Journal of Health Technologies
